Dublin, Jan. 12, 2017 -- Research and Markets has announced the addition of the "Hospital Acquired Infections Forecast in 15 Major Markets 2017-2027" report to their offering.
Hospital acquired infections (HAI), or nosocomial infections - infections acquired by patients or staff during in-patient care (hospital admission). This is the point or annual prevalence of HAI (or HCAI), equivalent to a number of cases of an infection per year. HAI can be caused by any pathogen, including bacteria, viruses and fungi.
This report provides the current incident population for Hospital Acquired Infections across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Netherlands, Sweden, Norway, Denmark, Finland, Poland, Romania, Czech Republic and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Hospital Acquired Infections have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line Incidence for Hospital Acquired Infections
10. HAI by major site of infection
11. HAI by main pathogen
12. Treatment of HAIs
13. Abbreviations used in the report
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/5scl45/hospital_acquired
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs


CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



